CliffBio
small molecule

SUFLAVE

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE

Loss of exclusivityAugust 2044latest FDA-listed patent expiry
CompanyAzurity Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameSUFLAVE
Active ingredientMAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE
Strength0.9GM/BOT;178.7GM/BOT;1.12GM/BOT;0.5GM/BOT;7.3GM/BOT
Dosage formFOR SOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalJune 2023
Marketing statusRX

Listed patents

PatentExpiresType
12290529August 2044product
12433914June 2044use U-4143
12239659June 2044use U-4143
12594298June 2044product

Regulatory exclusivity

CodeExpires
NPJune 2026

More from Azurity Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.